AmandaCashenMD

Oncology • Saint Louis, MO

Hematologic Oncology

Associate Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Cashen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cashen's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 314-454-8304

Fax+1 314-454-5902

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2003 - 2006
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2002
Washington University in St. Louis School of MedicineClass of 1999

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 2000 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Belinostat in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2006 May 01
Completed
Phase 2
Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma Start of enrollment: 2005 Feb 01
Completed
Not Applicable
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma Start of enrollment: 2008 Nov 01
Completed
Phase 1, Phase 2
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
Active, not recruiting
Phase 2
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 May 01
Completed
Phase 1
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma Start of enrollment: 2011 Apr 28
Completed
Phase 1
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
Completed
Phase 1, Phase 2
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma Start of enrollment: 2012 Jul 01
Terminated
Phase 1
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
Completed
Phase 1, Phase 2
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
Terminated
Phase 1, Phase 2
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2014 Sep 18
Completed
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2014 Jun 01
Completed
Early Phase 1
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Start of enrollment: 2015 Feb 04
Completed
Phase 1
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth Paietta, Susan O'Brien
Blood Advances. 2025-01-14
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
Meagan A Jacoby, Eric D Duncavage, Ajay Khanna, Gue Su Chang, Sridhar Nonavinkere Srivatsan
Leukemia. 2025-01-01
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for...
Nicole Foley, Peter A Riedell, Nancy L Bartlett, Amanda F Cashen, Brad S Kahl
Clinical Lymphoma, Myeloma & Leukemia. 2024-12-04

Journal Articles

The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL
Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood

Abstracts/Posters

Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplan...
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after...
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

$10.8 Million Grant Supports Cutting-Edge Leukemia ResearchDecember 16th, 2024
Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007December 5th, 2024
World Leaders in Ending Blood CancerNovember 14th, 2024
Join now to see all